It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver of UC, according to a Sept. 11 press release.
Tremfya is administered as a 200 milligram induction dose intravenously at weeks zero, four and eight by a healthcare professional.
It first received FDA approval in 2017 for the treatment of adult patients with moderate-to-severe plaque psoriasis.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
